POL regulation of drugs and vaccines
| Zeile 11: | Zeile 11: | ||
{{tp|p=32653276|t=2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.|pdf=|usr=015}} | {{tp|p=32653276|t=2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.|pdf=|usr=015}} | ||
{{tp|p=32654910|t=?. Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: The result of an overstocking procedure in French hospitals?|pdf=|usr=015}} | {{tp|p=32654910|t=?. Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: The result of an overstocking procedure in French hospitals?|pdf=|usr=015}} | ||
| + | {{tp|p=32716030|t=2020. National drug shortages worsen during COVID-19 crisis: Proposal for a comprehensive model to monitor and address critical drug shortages.|pdf=|usr=018}} | ||
| + | {{tp|p=32716795|t=2020. Compassionate Release as a "Right" in the Age of COVID-19.|pdf=|usr=014}} | ||
| + | {{tp|p=32733682|t=2020. 'Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences' by Roussel and Raoult (2020).|pdf=|usr=017}} | ||
| + | {{tp|p=32758342|t=2020. Were it business opportunities or hidden risks: Observations on clinical trials and marketing authorizations of Gilead Science's remdesivir in China.|pdf=|usr=017}} | ||
| + | {{tp|p=32763102|t=2020. Medication shortages during the COVID-19 pandemic: Saving more than COVID lives.|pdf=|usr=018}} | ||
| + | {{tp|p=32766736|t=2020. Unwavering Regulatory Safeguards for COVID-19 Vaccines.|pdf=|usr=017}} | ||
| + | {{tp|p=32773895|t=2020. Accelerating regulation in response to COVID-19.|pdf=|usr=017}} | ||
Version vom 7. Dezember 2020, 09:10 Uhr
- german professional petition to stop phase iii trial on pfizer vuckine scroll dona article to see original document.
32092455 2020. New regulatory strategies to manage medicines shortages in Europe.
32282038 2020. The VACCINES Act, Deciphering Vaccine Hesitancy in the Time of COVID19.
32406905 2020. Navigating regulatory statutes during the Coronavirus Disease 2019.
32509289 2020. The case for compulsory licensing during COVID-19.
32556334 2020. Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?
32577858 2020. Pricing vaccines and drugs in Europe: worth differentiating?
32617864 2020. Short and long term impacts of COVID-19 on the pharmaceutical sector.
32646713 2020. Why we should all be more careful in drawing conclusions about how COVID-19 is changing drug markets.
32651020 2020. COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use.
32653276 2020. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of protein vaccines.
32654910 ?. Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: The result of an overstocking procedure in French hospitals?
32716030 2020. National drug shortages worsen during COVID-19 crisis: Proposal for a comprehensive model to monitor and address critical drug shortages.
32716795 2020. Compassionate Release as a "Right" in the Age of COVID-19.
32733682 2020. 'Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences' by Roussel and Raoult (2020).
32758342 2020. Were it business opportunities or hidden risks: Observations on clinical trials and marketing authorizations of Gilead Science's remdesivir in China.
32763102 2020. Medication shortages during the COVID-19 pandemic: Saving more than COVID lives.
32766736 2020. Unwavering Regulatory Safeguards for COVID-19 Vaccines.
32773895 2020. Accelerating regulation in response to COVID-19.
